Description

Protac Bcl2 Degrader-1 CAS NO 2378801-85-3 is a potent and selective small-molecule degrader designed to target and eliminate Bcl-2 proteins via the ubiquitin-proteasome system. This targeted protein degradation (TPD) technology offers a novel therapeutic strategy beyond traditional inhibition, providing a powerful tool for oncology research and drug discovery. It is essential for pharmaceutical R&D teams, academic researchers, and biotechnology companies focused on developing next-generation cancer therapies, particularly for hematological malignancies and solid tumors where Bcl-2 overexpression drives resistance to apoptosis.

Application

• Oncology Research & Drug Discovery: A critical tool for investigating Bcl-2's role in cancer cell survival and for validating PROTAC (Proteolysis Targeting Chimera) as a therapeutic modality.
• Mechanistic Studies: Used to study the kinetics, efficiency, and specificity of targeted protein degradation compared to classical inhibition.
• Preclinical Development: Serves as a lead compound or benchmark for developing novel PROTAC-based therapeutics targeting anti-apoptotic proteins.
• Biomarker & Resistance Research: Employed in models to understand mechanisms of resistance to Bcl-2 family inhibitors and to identify predictive biomarkers.
• Chemical Biology: Utilized as a molecular probe to elucidate complex protein-protein interaction networks and downstream signaling pathways affected by Bcl-2 degradation.
• Combination Therapy Studies: Investigated in conjunction with other anticancer agents (e.g., chemotherapeutics, other targeted therapies) to assess synergistic effects.

Basic Information

Product Name	Protac Bcl2 Degrader-1
CAS No.	2378801-85-3
Molecular Formula	C47H55ClN6O7S
Molecular Weight	907.49 g/mol
Synonyms	PROTAC Bcl-2 Degrader-1; Bcl-2 Degrader-1; DT2216; ARV-110 (related PROTAC class); (S,R,S)-AHPC-Me-(PEG)2-C6-amide-N-(4-((4-(4-chlorophenyl)piperazin-1-yl)sulfonyl)phenyl)-4-(((4-(((S)-2-((S)-2-(6-methoxy-1H-indol-3-yl)-1-methyl-2-oxoethyl)amino)-1-methyl-2-oxoethyl)amino)methyl)cyclohexane-1-carboxamide; Bcl2-targeting PROTAC; Proteolysis-targeting chimera for Bcl-2
EINECS	Contact for details

Quality Control

Our Protac Bcl2 Degrader-1 is manufactured under strict quality systems to ensure batch-to-batch consistency and reliability for critical research applications. Each lot undergoes comprehensive analytical characterization, including HPLC purity analysis, mass spectrometry (MS) for identity confirmation, and nuclear magnetic resonance (NMR) spectroscopy. Certificates of Analysis (COA) detailing all specifications and test results are provided to guarantee the material meets the high standards required for pharmaceutical R&D and preclinical studies.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below under desiccant. This compound is hygroscopic (moisture-sensitive). Allow the vial to equilibrate to room temperature in a dry environment before opening to minimize moisture uptake. For long-term storage, keep containers sealed under an inert atmosphere such as argon or nitrogen.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC-MS)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.